Public Health, Access to HIV AIDS Medicines and WTO:The Doha Declaration and its Aftermath
Lakshimidevi Somnath
Public Health, Access to HIV AIDS Medicines and WTO: The Doha Declaration and its Aftermath
- Bangalore NLSIU 2003
- 161p
CONTENTS TABLE OF CASES; TABLE STATUTES; CHAPTER I; INTRODUCTION; CHAPTER II; RESEARCH METHODOLOGY; 2.1. Aims And Objectives; 2.2. Scope And Limitation; 2.3. Method or Analysis; 2.4. Sources of Data; 2.5 - Research Questions; 2.6. Mode or Citation; CHAPTER III; WTO AND THE NEW TRADE REGIME: THE TRIPS AGREEMENT; 3.1 - The Nature or Property As Intellectual Property; 3.2 - The Development of the Trips Agreement; 3.3 - Objectives and Principles of TRIPS; 3.4 - Pertinent Provisions of Trips And The Pharmaceutical Industry; 3.5 - The TRIPs Agreement and the Developing Nations; CHAPTER IV; THE PHARMACEUTICAL INDUSTRY AND DEVELOPING WORLD; 4.1 - The Global Pharmaceutical Situation; 4.2 - Pharmaceuticals In Developing Countries; 4.3 Medication The Pharmaceutical Industry And Access To Hiv / Aids medication; CHAPTER V; ACCESS TO HIV / AIDS DRUGS: A HUMAN RIGHTS PERSPECTIVE; 5.1 - Patent Protection For Pharmaceuticals And International Human Rights; 5.2 - Right To Health Care And Essential Medicines; 5.3 - HIV / AIDS Treatment Access & Human Rights; 5.4 - The Human Right Liability of Pharmaceutical Companies; 5.5 - HIV / AIDS Public Health Crisis as a National Emergency; CHAPTER VI; SOUTH AFRICA'S FIGHT FOR HIV / AIDS MEDICATION: AN ANALYSIS; 6.1 - History of HIV / AIDS Drug Availability in South Africa; 6.2 - The South African Response To Limited HIV / AIDS Drug Availability; 6.3 - Analysis of South Africa Medicines and Related Substances Control Amendment Act; 6.4 - Pharmaceutical Corporations v. South Africa: The Quest for Increased Drug Availability; 6.5 - The Final Outcome; CHAPTER VII; BATTLING THE AIDS CRISIS: THE EXPERIENCE OF OTHER DEVELOPING COUNTRIES; 7.1 – Brazil; 7.2 – Thailand; CHAPTER VIII; INDIA'S HISTORY AND CURRENT STATUS OF HIV/AIDS MEDICATION ; 8.1 - Patent Protection in India from 1970 to 2002; 8.2 - The Pharmaceutical Industry in India; 8.3 - The Indian Pharmaceutical Industry and the Doha Declaration CHAPTER IX; THE EVOLUTION OF THE DOHA DECLARATION TRIPS AND PUBLIC HEALTH ; 9.1 - The Content of the Declaration: The Role of Generic Medicines; 9.2 - The Role played by International Institutions; 9.3 - Role Played by Non - Governmental Organizations NGOs; 9.4. Role-played Organization of the Developing Country Group ; 9.5 - Meeting of the TRIPs Council - 20 June 2001; 9.6. Interim Preparations; 9.7. Intervention of Anthrax and Cipro; 9.8 - The Meeting on 27 October 2001; CHAPTER X; THE MANDATE OF THE DOHA DECLARATION OF TRIPS AND PUBLIC HEALTH; 10.1 - An Analysis of Doha Declaration; 10.2 - Drug Industry Response to the WTO Declaration on TRIPS and Public Health; CHAPTER XI; THE LEGAL ANALYSIS OF THE DOHA DECLARATION ON TRIPS AND PUBLIC HEALTH; 11.1 - The Doha Declaration of Evidence under Subsequent Practice TRIPS; 11.2 - The Doha Declaration as a Legally Non - Binding Statement of Intent and Commitment; CHAPTER XII; AFTERMAT TRIPS AND PUBLIC HEALTH ON DECLARATION: THE POST. DOHA AGENDA; 12.1 Issue an Official Interpretation on Public Health; 12.2 Designate WHO's Official Organization to Provide Technical Assistance on TRIPs - Related Health Issues; 12.3 Issue a Formal Interpretative Statement Clarifying TRIPS Article 30 Exceptions; 12.4 Safeguards Against Abuse Must Be Implemented; 12.5 Compile a Database of Generic Products; 12.6 - WTO Ministerial Meeting at Sydney; 12.7 TRIPS Council Meeting in November 2002; CHAPTER XIII; CONCLUSION; BIBLIOGRAPHY; Articles; Books; Agreements; Constitutions; Covenant; Declaration; Internet references; Press releases; Reports Miscellaneous.
HIV / AIDS Medication - India Pharmaceutical Industry - Developing World Right to health Card WTO- TRIPS- Public Health